Key facts
as of Sep 2026- It has raised $10.8M; the latest was Seed Round ($3.5M) in Jul 2025.
- Notable investors include European Union, Pradeyrol Developpement, L'Agence Nationale de la Recherche, Sofimac Investment Managers.
- 3 institutional filers report fund marks on Imaxio across 13 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Imaxio
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Imaxio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
3 filers · latest May 20263 SEC-registered funds reported 13 fair-value marks on Imaxio between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Imaxio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Imaxio
Developer of medicinal products and vaccines designed to treat human leptospirosis. The company's preclinical-stage products are based on an antigen re-engineering platform to improve immunogenicity, enabling patients to improve their immune response to immunogenic antigens.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2000
- Employees
- 23
- Website
- imaxio.fr/
- Ownership
- Privately Held (backing)